Mana Capital Acquisition (MAAQ) Competitors $4.15 -0.14 (-3.26%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MAAQ vs. SKYE, ACTU, TARA, BHST, ATOS, CRDL, PLX, TNYA, HURA, and MCRBShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Skye Bioscience (SKYE), Actuate Therapeutics (ACTU), Protara Therapeutics (TARA), BioHarvest Sciences (BHST), Atossa Genetics (ATOS), Cardiol Therapeutics (CRDL), Protalix BioTherapeutics (PLX), Tenaya Therapeutics (TNYA), TuHURA Biosciences (HURA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Its Competitors Skye Bioscience Actuate Therapeutics Protara Therapeutics BioHarvest Sciences Atossa Genetics Cardiol Therapeutics Protalix BioTherapeutics Tenaya Therapeutics TuHURA Biosciences Seres Therapeutics Skye Bioscience (NASDAQ:SKYE) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment. Do insiders & institutionals hold more shares of SKYE or MAAQ? 21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 3.0% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate SKYE or MAAQ? Skye Bioscience presently has a consensus target price of $16.60, suggesting a potential upside of 349.86%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Skye Bioscience is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, SKYE or MAAQ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$0.82-4.50Mana Capital AcquisitionN/AN/AN/AN/AN/A Does the media refer more to SKYE or MAAQ? In the previous week, Skye Bioscience had 3 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 3 mentions for Skye Bioscience and 0 mentions for Mana Capital Acquisition. Skye Bioscience's average media sentiment score of 0.63 beat Mana Capital Acquisition's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media. Company Overall Sentiment Skye Bioscience Positive Mana Capital Acquisition Neutral Is SKYE or MAAQ more profitable? Mana Capital Acquisition's return on equity of 0.00% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -53.92% -48.58% Mana Capital Acquisition N/A N/A N/A SummarySkye Bioscience beats Mana Capital Acquisition on 6 of the 9 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$33.72M$33.72M$2.17B$9.31BDividend YieldN/AN/A2.60%4.03%P/E RatioN/AN/A22.2719.73Price / SalesN/AN/A96.54174.27Price / CashN/AN/A13.3957.96Price / BookN/AN/A77.985.67Net IncomeN/AN/A-$134.41M$257.79M7 Day Performance9.50%9.50%0.07%0.52%1 Month Performance2.22%2.22%1.15%8.84%1 Year Performance657.30%657.30%20.31%14.18% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$4.15-3.3%N/A+657.3%$33.72MN/A0.001SKYESkye Bioscience2.1385 of 5 stars$3.98+1.0%$16.60+317.1%-40.6%$122.04MN/A-4.8511ACTUActuate Therapeutics2.916 of 5 stars$6.14-0.6%$20.50+233.9%N/A$121.25MN/A0.0010Positive NewsTARAProtara Therapeutics2.0692 of 5 stars$3.05-2.2%$20.50+572.1%+28.2%$120.38MN/A-1.7730BHSTBioHarvest SciencesN/A$7.18-0.6%$13.67+90.3%N/A$118.59M$25.19M-14.36N/AATOSAtossa Genetics3.1424 of 5 stars$0.94+5.7%$6.17+557.1%-34.7%$114.69MN/A-4.478Positive NewsCRDLCardiol Therapeutics2.4251 of 5 stars$1.29-5.8%$8.00+520.2%-39.4%$113.23MN/A-3.7920Positive NewsPLXProtalix BioTherapeutics2.801 of 5 stars$1.41-4.7%$15.00+963.8%+19.0%$112.25M$59.76M-10.85200TNYATenaya Therapeutics3.4095 of 5 stars$0.68-0.7%$6.25+814.8%-80.4%$111.88MN/A-0.59110HURATuHURA Biosciences1.3657 of 5 stars$2.30-8.7%$12.67+450.7%N/A$110.07MN/A0.00N/AMCRBSeres Therapeutics3.4491 of 5 stars$12.57+1.8%$73.67+486.1%-38.4%$107.85M$126.32M-2.73330Positive News Related Companies and Tools Related Companies SKYE Alternatives ACTU Alternatives TARA Alternatives BHST Alternatives ATOS Alternatives CRDL Alternatives PLX Alternatives TNYA Alternatives HURA Alternatives MCRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
